ICLR

ICON releases its 2022 ICON Cares ESG Report

Retrieved on: 
Tuesday, May 16, 2023
DEI (Diversity, Equity and Inclusion), Pharmaceutical, Sustainability, Environment, Finance, Health, Professional Services, Clinical Trials, United Nations Sustainable Development Group, F-1, Science, Thurgood Marshall College Fund, Science Based Targets initiative, Partnership, Corporate social responsibility, Public, Workplace, COVID-19, Silver, F-3, Intelligence, GHG, Targets, Social Security Government Pension Offset, School, Parity, Student, F-4, Patient, ICLR, STEM, Historically black colleges and universities, S-8, ESG, Social, Letter, ICON PLC, Female, Nursing, Management, ICON, University, Diversity

ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2022 Environmental, Social and Governance (ESG) Report .

Key Points: 
  • ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today releases its ICON Cares 2022 Environmental, Social and Governance (ESG) Report .
  • The company’s ICON Cares initiative incorporates its ESG, Diversity, Inclusion and Belonging and Corporate Social Responsibility initiatives under one program.
  • The report provides an overview of ICON’s ESG activities in 2022 and the progress it has made in advancing its ESG priorities.
  • In recognition of progress made in its ESG efforts, in 2022, ICON was awarded a silver medal by EcoVadis , a leading provider of business sustainability ratings.

IEEE Computer Society Emerging Technology Fund Recipient Introduces Machine Learning Cybersecurity Benchmarks

Retrieved on: 
Friday, May 5, 2023
Tao, IEEE Smart Grid, Science, IEEE CS, University, Texas Emerging Technology Fund, Deep learning, University of Illinois Urbana-Champaign, Harbin Institute of Technology, Intelligence, Dakota State University, Research, Computer, IEEE, Machine learning, TRC, Computer engineering, Goldey–Beacom College, Dakota, ICLR, Tsinghua University, Artificial intelligence, Poisoning, LOS, AI, Nanyang Technological University, Conference, Electricity, Institute of Electrical and Electronics Engineers, Arms industry, Risk management, Medical device, Virginia Tech, Privacy

LOS ALAMITOS, Calif., May 5, 2023 /PRNewswire/ -- Today, at the virtual Backdoor Attacks and Defenses in Machine Learning (BANDS) workshop during The Eleventh International Conference on Learning Representations (ICLR), participants in the IEEE Trojan Removal Competition presented their findings and success rates at effectively and efficiently mitigating the effects of neural trojans while maintaining high performance. Evaluated on clean accuracy, poisoned accuracy, and attack success rate, the competition's winning team from the Harbin Institute of Technology in Shenzhen, with set HZZQ Defense, formulated a highly effective solution, resulting in a 98.14% poisoned accuracy rate and only a 0.12% attack success rate. This group will be awarded the first-place prize of $5,000 USD.

Key Points: 
  • He also was named the distinguished contributor of IEEE Computer Society in 2021.
  • In 2022, IEEE CS established its Emerging Technology Fund, and for the first time, awarded $25,000 USD to IEEE SCSTC for the "Annual Competition on Emerging Issues of Data Security and Privacy (EDISP)," which yielded the IEEE Trojan Removal Competition (TRC '22).
  • "This is precisely the kind of work we want the Emerging Technology Fund to fuel," said Nita Patel, 2023 IEEE Computer Society President.
  • "It goes a long way toward bolstering iterative developments that will strengthen the security of machine learning and AI platforms as the technologies advance."

ICON Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, April 26, 2023
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Medical Devices, Professional Services, F-1, COVID-19, Calendar, AND, F-3, GAAP, Medicine, EDT, Government, EBITDA, F-4, ICLR, S-8, Growth, ICON PLC, UK, Pharmaceutical industry, Bank, Video game, ICON

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2023.

Key Points: 
  • ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2023.
  • CEO, Dr. Steve Cutler commented, “ICON’s first quarter results reflect continued demand for our broad portfolio of services despite the challenging macroeconomic environment.
  • GAAP net income attributable to the Group was $116.7 million resulting in $1.41 diluted earnings per share in quarter one 2023 compared to $1.36 diluted earnings per share in quarter one 2022.
  • With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 109 locations in 53 countries as at March 31, 2023.

ICON plc Schedules First Quarter 2023 Earnings Conference Call

Retrieved on: 
Wednesday, March 29, 2023
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Medical Devices, Professional Services, ICLR, ICON PLC, Pharmaceutical industry, Broadcasting

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2023 after the market closes on Wednesday, April 26, 2023.

Key Points: 
  • ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the first quarter 2023 after the market closes on Wednesday, April 26, 2023.
  • The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, April 27, 2023 at 8:00am ET.
  • Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “ Events ”.
  • A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.

LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology

Retrieved on: 
Friday, March 10, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Partnership, FSP, ICLR, Dermatology, PACE, Clinical trial, ICON, Patient, Head, LEO, Leo Pharma, Communication, Laboratory, Pharmaceutical industry, Fine chemical

LEO Pharma , a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.

Key Points: 
  • LEO Pharma , a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
  • The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges.
  • Building on earlier collaboration successes within psoriasis trials, LEO Pharma expect to further strengthen its transformation journey by entering a strategic partnership with ICON.
  • “ICON is delighted to enter this partnership with LEO Pharma that truly takes advantage of our breadth of capability and expertise.

LEO Pharma and ICON Enter a Strategic Partnership to Propel Clinical Trial Execution Within Medical Dermatology

Retrieved on: 
Friday, March 10, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Partnership, FSP, Multimedia, ICLR, Dermatology, PACE, Clinical trial, ICON, Patient, Head, LEO, Leo Pharma, Communication, Laboratory, Pharmaceutical industry, Fine chemical

LEO Pharma , a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.

Key Points: 
  • LEO Pharma , a global leader in medical dermatology, and ICON plc (NASDAQ: ICLR) today announced a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, and which will support the company’s overall ambition of building one of the most effective and efficient clinical portfolio execution organisations in the industry.
  • The partnership will operate under the acronym of PACE, reflecting the requirement to move quickly to address today’s clinical development challenges.
  • Building on earlier collaboration successes within psoriasis trials, LEO Pharma expects to further strengthen its transformation journey by entering a strategic partnership with ICON.
  • “ICON is delighted to enter this partnership with LEO Pharma that truly takes advantage of our breadth of capability and expertise.

ICON plc to Present at Upcoming Investor Conferences

Retrieved on: 
Monday, February 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Clinical Trials, ICON PLC, Conference, ICLR, CFO, Pharmaceutical industry, Medical device, ICON

ICON plc , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2023 Citi Healthcare Conference on Thursday, March 2, 2023 at 2pm ET.

Key Points: 
  • ICON plc , (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at the 2023 Citi Healthcare Conference on Thursday, March 2, 2023 at 2pm ET.
  • Dr. Steve Cutler, CEO of ICON plc, will present at the Barclays Global Healthcare Conference on Wednesday, March 15, 2023.
  • The presentation will be webcast live from 1.35pm ET.

ICON plc Schedules Fourth Quarter 2022 Earnings Conference Call

Retrieved on: 
Thursday, January 26, 2023
Science, Research, Finance, General Health, Health, Professional Services, Clinical Trials, Other Health, ICON PLC, ICLR, Pharmaceutical industry, Broadcasting

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the fourth quarter 2022 after the market closes on Wednesday, February 22, 2023.

Key Points: 
  • ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced that it will release its financial results for the fourth quarter 2022 after the market closes on Wednesday, February 22, 2023.
  • The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 23, 2023 at 8:00am ET.
  • Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under “ Events ”.
  • A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.

Snorkel AI Heads Into 2023 With Record Momentum and Growth

Retrieved on: 
Wednesday, January 18, 2023
Professional Services, Data Management, Technology, Software, Finance, Venture Capital, Artificial Intelligence, Momentum, Classification, Ecosystem, Conference on Neural Information Processing Systems, University of Washington, State Farm, Snowflake, Data, University, Student, Insurance, Continuous modelling, Meta, Data-centric programming language, ML, Comcast, Capital One, Organization, CSET, Center for Security and Emerging Technology, Stanford University, Georgetown University in Qatar, PDF, Databricks, Research, University of Wisconsin–Madison, AstraZeneca, Government, Conference, Health, ACL, CIA, Ford Motor Company, Fortune 500, JPMorgan Chase, Automation, ICLR, Microsoft, BigQuery, Fake Four Inc., Brown University, BNY Mellon, NLP, Rhinestone Cowboy (New Studio Recordings), Data science, Multimedia, Science and technology in Asia, Security, Medical device, AI, NVIDIA, Growth, Apple

Snorkel AI , the data-centric AI platform company, today announced record 2022 business momentum, led by triple-digit customer growth.

Key Points: 
  • Snorkel AI , the data-centric AI platform company, today announced record 2022 business momentum, led by triple-digit customer growth.
  • View the full release here: https://www.businesswire.com/news/home/20230118005384/en/
    Snorkel AI Heads Into 2023 With Record Momentum and Growth (Graphic: Business Wire)
    Enterprise data science and machine learning teams use Snorkel Flow , the company’s flagship AI platform powered by programmatic labeling, to accelerate AI application development by 10-100x.
  • “The rate of progress in AI is accelerating, especially with foundation models,” said Alex Ratner, CEO and co-founder, Snorkel AI.
  • Expanded Partnership Ecosystem: Snorkel AI deepened partnerships across the enterprise AI ecosystem including Microsoft Azure AI Services, Google BigQuery and Vertex AI, Snowflake, Aimpoint Digital, Four Inc. and more.

ICON Issues Financial Guidance for Full Year 2023

Retrieved on: 
Tuesday, January 10, 2023
Professional Services, Finance, Public expenditure, Growth, ICON plc, Environment, ICLR, Share repurchase, Pharmaceutical industry

ICON plc , (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2023.

Key Points: 
  • ICON plc , (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2023.
  • Our outlook for 2023 reflects a continued solid demand environment albeit with persistent macroeconomic challenges, resulting in full year revenue guidance in the range of $7,940 - $8,340 million and adjusted earnings per share1 guidance in the range of $12.40 - $13.05.”
    Full year 2023 financial guidance assumptions:
    Circa $1.1 billion of free cash flow and capital expenditures of circa $200 million.
  • Excludes any potential share repurchase or M&A activity in the above guidance.
  • With respect to full year 2022, the company reaffirmed its current guidance of revenue in the range of $7,690 - $7,810 million and adjusted earnings per share1 in the range of $11.65 - $11.85.